CA
QNCX icon

CoreCap Advisors’s Quince Therapeutics QNCX Stock Holding History

CoreCap Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$335 – 2953
2024
Q3 		$335 Hold
2
– – ﹤0.01% 2413
2024
Q2 		$323 Hold
2
– – ﹤0.01% 1479
2024
Q1 		$457 Buy
+2
New +$497 ﹤0.01% 2345
2022
Q4 		$275 Buy
+2
New +$334 ﹤0.01% 2244
2022
Q3 		– Sell
-2
Closed -$1K – 1702
2022
Q2 		$1K Buy
+2
New +$1.41K ﹤0.01% 2039
2022
Q1 		– Sell
-2
Closed -$5K – 1702
2021
Q4 		$5K Buy
+2
New +$12.2K ﹤0.01% 1758

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CoreCap Advisors's QNCX Position: Q4 2024 in Review

CoreCap Advisors sold out of Quince Therapeutics (QNCX) in Q4 2024, closing a stake of 2 shares — an estimated $335 sold.

CoreCap Advisors first reported a position in QNCX in Q4 2021 and held it in 6 quarters. The position peaked at $5K in Q4 2021. 33 funds tracked by Wall St. Rank hold QNCX as of Q4 2024.

  • CoreCap Advisors reported no remaining Quince Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CoreCap Advisors sold 2 Quince Therapeutics shares in Q4 2024, an estimated $335.
  • CoreCap Advisors first reported a position in Quince Therapeutics in Q4 2021 and held it in 6 quarters.
  • CoreCap Advisors's Quince Therapeutics position peaked at $5K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2024.

Based on CoreCap Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.